- Home
- SABS vs RMCO Comparison
SABS vs RMCO Comparison
Compare SABS & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- RMCO
- Stock Information
- Founded
- SABS 2014
- RMCO 2021
- Country
- SABS United States
- RMCO United States
- Employees
- SABS N/A
- RMCO N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- RMCO Multi-Sector Companies
- Sector
- SABS Health Care
- RMCO Miscellaneous
- Exchange
- SABS Nasdaq
- RMCO Nasdaq
- Market Cap
- SABS 15.8M
- RMCO 14.9M
- IPO Year
- SABS N/A
- RMCO N/A
- Fundamental
- Price
- SABS $2.02
- RMCO $1.65
- Analyst Decision
- SABS Strong Buy
- RMCO
- Analyst Count
- SABS 5
- RMCO 0
- Target Price
- SABS $10.00
- RMCO N/A
- AVG Volume (30 Days)
- SABS 4.3M
- RMCO 66.4K
- Earning Date
- SABS 08-07-2025
- RMCO 08-11-2025
- Dividend Yield
- SABS N/A
- RMCO 0.31%
- EPS Growth
- SABS N/A
- RMCO N/A
- EPS
- SABS N/A
- RMCO N/A
- Revenue
- SABS $114,698.00
- RMCO $2,641,171.00
- Revenue This Year
- SABS N/A
- RMCO N/A
- Revenue Next Year
- SABS N/A
- RMCO N/A
- P/E Ratio
- SABS N/A
- RMCO N/A
- Revenue Growth
- SABS N/A
- RMCO 292.46
- 52 Week Low
- SABS $1.00
- RMCO $0.76
- 52 Week High
- SABS $6.60
- RMCO $1.88
- Technical
- Relative Strength Index (RSI)
- SABS 42.28
- RMCO 66.56
- Support Level
- SABS $1.85
- RMCO $1.28
- Resistance Level
- SABS $2.26
- RMCO $1.53
- Average True Range (ATR)
- SABS 0.26
- RMCO 0.11
- MACD
- SABS -0.06
- RMCO 0.02
- Stochastic Oscillator
- SABS 16.71
- RMCO 96.58
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.